Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Matheson

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Nature Communications|December 11, 2025
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumabAndrew Blauvelt, Rundong Jiang, Linyu Shi, et al.
Journal of Vascular Surgery Cases and Innovative Techniques|May 8, 2023
A novel, microvascular evaluation method and device for early diagnosis of peripheral artery disease and chronic limb-threatening ischemia in individuals with diabetesBenjamin T Matheson, Robin B Osofsky, Debra M Friedrichsen, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisHoward Sofen, Stacy Smith, Robert T Matheson, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
Immunity|May 28, 2026
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuitRundong Jiang, Andrew Blauvelt, Linyu Shi, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Nature Communications|December 11, 2025
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumabAndrew Blauvelt, Rundong Jiang, Linyu Shi, et al.
Journal of Vascular Surgery Cases and Innovative Techniques|May 8, 2023
A novel, microvascular evaluation method and device for early diagnosis of peripheral artery disease and chronic limb-threatening ischemia in individuals with diabetesBenjamin T Matheson, Robin B Osofsky, Debra M Friedrichsen, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisHoward Sofen, Stacy Smith, Robert T Matheson, et al.
Archives of Dermatology|December 17, 2003
A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb, Robert T Matheson, Nicholas Lowe, et al.
Immunity|May 28, 2026
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuitRundong Jiang, Andrew Blauvelt, Linyu Shi, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
Pageof 6